Nuveen’s abrdn Life Sciences Investors HQL Stock Holding History

Nuveen’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$9.6K	Buy	+520	New	+$10.5K	﹤0.01%	4562

Other funds holding HQL

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Flagship Harbor Advisors Boston, Massachusetts $2.69B AUM 15.82% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Formidable Asset Management Cincinnati, Ohio $680M AUM 8.59% 1-Year Est. Return

180 Wealth Advisors Federal Way, Washington $1.04B AUM 41.44% 1-Year Est. Return

Blue Bell Private Wealth Management Blue Bell, Pennsylvania $840M AUM 13.7% 1-Year Est. Return

UHLMANN PRICE SECURITIES Skokie, Illinois $1.86B AUM 66.72% 1-Year Est. Return

Z3 Capital Partners Richmond, Virginia $482M AUM 40.01% 1-Year Est. Return

City of London Investment Management London, United Kingdom $1.47B AUM 36.54% 1-Year Est. Return

Closed-End Fund Advisors Richmond, Virginia $96.2M AUM 6.01% 1-Year Est. Return

Nuveen's HQL Position: Q3 2026 in Review

Nuveen opened a new position in abrdn Life Sciences Investors (HQL) in Q3 2026: 520 shares worth $9.6K. The stake represents ﹤0.01% of the portfolio and ranks #4562 among its holdings.

47 funds tracked by Wall St. Rank hold HQL as of Q3 2026.

Nuveen held 520 shares of abrdn Life Sciences Investors worth $9.6K as of Q3 2026.
abrdn Life Sciences Investors was a new Nuveen position in Q3 2026.
abrdn Life Sciences Investors made up ﹤0.01% of Nuveen's portfolio in Q3 2026, its #4562 holding.
47 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.